Fig. 1

ATO and DEX in CSDH patients. a ATO concentration in haematoma fluids and serum samples of patients who were switched to surgery, ATO (haematoma vs. serum, Mann–Whitney U test, ^*P = 0.03); ATO + DEX (haematoma vs. serum, Mann–Whitney U test, ^**P = 0.008); haematoma (ATO vs. ATO + DEX, Mann–Whitney U test, ^***P = 0.001); serum (ATO vs. ATO + DEX, Mann–Whitney U test, ^*P = 0.026). b Serum ATO in patients who responded well to the drug treatments and those who switched to surgery, ATO (switch to surgery vs. respond well to drug treatments, Mann–Whitney U test, ^*P = 0.046); ATO + DEX (switch to surgery vs. respond well to drug treatments, Mann–Whitney U test, ^**P = 0.006); switch to surgery (ATO vs. ATO + DEX, Mann–Whitney U test, ^*P = 0.026); respond well to drug treatments (ATO vs. ATO + DEX, Mann–Whitney U test, ^**P = 0.007). c DEX concentration in patients who responded well to the drug treatments and those who switched to surgery. Note: ATO, atorvastatin monotherapy group; ATO + DEX, combination group treated with atorvastatin and low-dose dexamethasone